Please assess the completion status of the following clinical trial:

Trial Title: Erythropoietin Protects Very Preterm Infants Against Necrotizing Enterocolitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Preterm infants with gestation age ≤ 32weeks~* Within 72 hours after birth~* Written informed consent obtained from parents~Exclusion Criteria:~* Genetic or metabolic diseases~* Congenital abnormalities~* Polycythemia~* Intracranial hemorrhage grade III/IV~* Unstable vital signs (such as respiration and circulation failure)

- Gender: ALL
- Minimum Age: None
- Maximum Age: 72 Hours
- Healthy Volunteers: f

Study Arms:
- Erythropoietin (Type: EXPERIMENTAL): Infants in the EPO group are given EPO 500IU/kg dissolved in 2 ml saline intravenously every other day for 2 weeks starting within 72 hours after birth.
- Normal saline (Type: PLACEBO_COMPARATOR): Infants in the control group are given normal saline intravenously with the same volume as EPO every other day for 2 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).